Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.
Identifieur interne : 001F45 ( PubMed/Curation ); précédent : 001F44; suivant : 001F46Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.
Auteurs : Taisheng Li [République populaire de Chine] ; Jing Xie ; Yuxian He ; Hongwei Fan ; Laurence Baril ; Zhifeng Qiu ; Yang Han ; Wenbing Xu ; Weihong Zhang ; Hui You ; Yanling Zuo ; Qing Fang ; Jian Yu ; Zhiwei Chen ; Linqi ZhangSource :
- PloS one [ 1932-6203 ] ; 2006.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Anticorps antiviraux (sang), Antigènes viraux (génétique), Données de séquences moléculaires, Facteurs temps, Femelle, Fréquence d'allèle, Gènes MHC de classe I, Gènes MHC de classe II, Humains, Immunoglobuline G (sang), Lymphocytes T cytotoxiques (immunologie), Mâle, Protéines nucléocapside (génétique), Protéines nucléocapside (immunologie), Spécificité des anticorps, Syndrome respiratoire aigu sévère (génétique), Syndrome respiratoire aigu sévère (immunologie), Syndrome respiratoire aigu sévère (virologie), Séquence d'acides aminés, Virus du SRAS (génétique), Virus du SRAS (immunologie), Épitopes (génétique), Études cas-témoins, Études de suivi.
- MESH :
- génétique : Antigènes viraux, Protéines nucléocapside, Syndrome respiratoire aigu sévère, Virus du SRAS, Épitopes.
- immunologie : Lymphocytes T cytotoxiques, Protéines nucléocapside, Syndrome respiratoire aigu sévère, Virus du SRAS.
- sang : Anticorps antiviraux, Immunoglobuline G.
- virologie : Syndrome respiratoire aigu sévère.
- Adulte, Adulte d'âge moyen, Données de séquences moléculaires, Facteurs temps, Femelle, Fréquence d'allèle, Gènes MHC de classe I, Gènes MHC de classe II, Humains, Mâle, Spécificité des anticorps, Séquence d'acides aminés, Études cas-témoins, Études de suivi.
English descriptors
- KwdEn :
- Adult, Amino Acid Sequence, Antibodies, Viral (blood), Antibody Specificity, Antigens, Viral (genetics), Case-Control Studies, Epitopes (genetics), Female, Follow-Up Studies, Gene Frequency, Genes, MHC Class I, Genes, MHC Class II, Humans, Immunoglobulin G (blood), Male, Middle Aged, Molecular Sequence Data, Nucleocapsid Proteins (genetics), Nucleocapsid Proteins (immunology), SARS Virus (genetics), SARS Virus (immunology), Severe Acute Respiratory Syndrome (genetics), Severe Acute Respiratory Syndrome (immunology), Severe Acute Respiratory Syndrome (virology), T-Lymphocytes, Cytotoxic (immunology), Time Factors.
- MESH :
- chemical , blood : Antibodies, Viral, Immunoglobulin G.
- chemical , genetics : Antigens, Viral, Epitopes, Nucleocapsid Proteins.
- chemical , immunology : Nucleocapsid Proteins.
- genetics : SARS Virus, Severe Acute Respiratory Syndrome.
- immunology : SARS Virus, Severe Acute Respiratory Syndrome, T-Lymphocytes, Cytotoxic.
- virology : Severe Acute Respiratory Syndrome.
- Adult, Amino Acid Sequence, Antibody Specificity, Case-Control Studies, Female, Follow-Up Studies, Gene Frequency, Genes, MHC Class I, Genes, MHC Class II, Humans, Male, Middle Aged, Molecular Sequence Data, Time Factors.
Abstract
Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention. However, the immunological correlates associated with patients' recovery are currently unknown. In this report, we have sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our findings have direct implications for future design and development of effective therapeutic agents and vaccines against SARS-CoV infection.
DOI: 10.1371/journal.pone.0000024
PubMed: 17183651
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001F45
Links to Exploration step
pubmed:17183651Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.</title><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease, Peking Union Medical College Hospital and AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. litsh@263.net</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Disease, Peking Union Medical College Hospital and AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Xie, Jing" sort="Xie, Jing" uniqKey="Xie J" first="Jing" last="Xie">Jing Xie</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Fan, Hongwei" sort="Fan, Hongwei" uniqKey="Fan H" first="Hongwei" last="Fan">Hongwei Fan</name></author><author><name sortKey="Baril, Laurence" sort="Baril, Laurence" uniqKey="Baril L" first="Laurence" last="Baril">Laurence Baril</name></author><author><name sortKey="Qiu, Zhifeng" sort="Qiu, Zhifeng" uniqKey="Qiu Z" first="Zhifeng" last="Qiu">Zhifeng Qiu</name></author><author><name sortKey="Han, Yang" sort="Han, Yang" uniqKey="Han Y" first="Yang" last="Han">Yang Han</name></author><author><name sortKey="Xu, Wenbing" sort="Xu, Wenbing" uniqKey="Xu W" first="Wenbing" last="Xu">Wenbing Xu</name></author><author><name sortKey="Zhang, Weihong" sort="Zhang, Weihong" uniqKey="Zhang W" first="Weihong" last="Zhang">Weihong Zhang</name></author><author><name sortKey="You, Hui" sort="You, Hui" uniqKey="You H" first="Hui" last="You">Hui You</name></author><author><name sortKey="Zuo, Yanling" sort="Zuo, Yanling" uniqKey="Zuo Y" first="Yanling" last="Zuo">Yanling Zuo</name></author><author><name sortKey="Fang, Qing" sort="Fang, Qing" uniqKey="Fang Q" first="Qing" last="Fang">Qing Fang</name></author><author><name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2006">2006</date><idno type="RBID">pubmed:17183651</idno><idno type="pmid">17183651</idno><idno type="doi">10.1371/journal.pone.0000024</idno><idno type="wicri:Area/PubMed/Corpus">001F45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001F45</idno><idno type="wicri:Area/PubMed/Curation">001F45</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001F45</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.</title><author><name sortKey="Li, Taisheng" sort="Li, Taisheng" uniqKey="Li T" first="Taisheng" last="Li">Taisheng Li</name><affiliation wicri:level="1"><nlm:affiliation>Department of Infectious Disease, Peking Union Medical College Hospital and AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. litsh@263.net</nlm:affiliation><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Infectious Disease, Peking Union Medical College Hospital and AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing</wicri:regionArea></affiliation></author><author><name sortKey="Xie, Jing" sort="Xie, Jing" uniqKey="Xie J" first="Jing" last="Xie">Jing Xie</name></author><author><name sortKey="He, Yuxian" sort="He, Yuxian" uniqKey="He Y" first="Yuxian" last="He">Yuxian He</name></author><author><name sortKey="Fan, Hongwei" sort="Fan, Hongwei" uniqKey="Fan H" first="Hongwei" last="Fan">Hongwei Fan</name></author><author><name sortKey="Baril, Laurence" sort="Baril, Laurence" uniqKey="Baril L" first="Laurence" last="Baril">Laurence Baril</name></author><author><name sortKey="Qiu, Zhifeng" sort="Qiu, Zhifeng" uniqKey="Qiu Z" first="Zhifeng" last="Qiu">Zhifeng Qiu</name></author><author><name sortKey="Han, Yang" sort="Han, Yang" uniqKey="Han Y" first="Yang" last="Han">Yang Han</name></author><author><name sortKey="Xu, Wenbing" sort="Xu, Wenbing" uniqKey="Xu W" first="Wenbing" last="Xu">Wenbing Xu</name></author><author><name sortKey="Zhang, Weihong" sort="Zhang, Weihong" uniqKey="Zhang W" first="Weihong" last="Zhang">Weihong Zhang</name></author><author><name sortKey="You, Hui" sort="You, Hui" uniqKey="You H" first="Hui" last="You">Hui You</name></author><author><name sortKey="Zuo, Yanling" sort="Zuo, Yanling" uniqKey="Zuo Y" first="Yanling" last="Zuo">Yanling Zuo</name></author><author><name sortKey="Fang, Qing" sort="Fang, Qing" uniqKey="Fang Q" first="Qing" last="Fang">Qing Fang</name></author><author><name sortKey="Yu, Jian" sort="Yu, Jian" uniqKey="Yu J" first="Jian" last="Yu">Jian Yu</name></author><author><name sortKey="Chen, Zhiwei" sort="Chen, Zhiwei" uniqKey="Chen Z" first="Zhiwei" last="Chen">Zhiwei Chen</name></author><author><name sortKey="Zhang, Linqi" sort="Zhang, Linqi" uniqKey="Zhang L" first="Linqi" last="Zhang">Linqi Zhang</name></author></analytic><series><title level="j">PloS one</title><idno type="eISSN">1932-6203</idno><imprint><date when="2006" type="published">2006</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Amino Acid Sequence</term><term>Antibodies, Viral (blood)</term><term>Antibody Specificity</term><term>Antigens, Viral (genetics)</term><term>Case-Control Studies</term><term>Epitopes (genetics)</term><term>Female</term><term>Follow-Up Studies</term><term>Gene Frequency</term><term>Genes, MHC Class I</term><term>Genes, MHC Class II</term><term>Humans</term><term>Immunoglobulin G (blood)</term><term>Male</term><term>Middle Aged</term><term>Molecular Sequence Data</term><term>Nucleocapsid Proteins (genetics)</term><term>Nucleocapsid Proteins (immunology)</term><term>SARS Virus (genetics)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (genetics)</term><term>Severe Acute Respiratory Syndrome (immunology)</term><term>Severe Acute Respiratory Syndrome (virology)</term><term>T-Lymphocytes, Cytotoxic (immunology)</term><term>Time Factors</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Anticorps antiviraux (sang)</term><term>Antigènes viraux (génétique)</term><term>Données de séquences moléculaires</term><term>Facteurs temps</term><term>Femelle</term><term>Fréquence d'allèle</term><term>Gènes MHC de classe I</term><term>Gènes MHC de classe II</term><term>Humains</term><term>Immunoglobuline G (sang)</term><term>Lymphocytes T cytotoxiques (immunologie)</term><term>Mâle</term><term>Protéines nucléocapside (génétique)</term><term>Protéines nucléocapside (immunologie)</term><term>Spécificité des anticorps</term><term>Syndrome respiratoire aigu sévère (génétique)</term><term>Syndrome respiratoire aigu sévère (immunologie)</term><term>Syndrome respiratoire aigu sévère (virologie)</term><term>Séquence d'acides aminés</term><term>Virus du SRAS (génétique)</term><term>Virus du SRAS (immunologie)</term><term>Épitopes (génétique)</term><term>Études cas-témoins</term><term>Études de suivi</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Viral</term><term>Immunoglobulin G</term></keywords><keywords scheme="MESH" type="chemical" qualifier="genetics" xml:lang="en"><term>Antigens, Viral</term><term>Epitopes</term><term>Nucleocapsid Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Nucleocapsid Proteins</term></keywords><keywords scheme="MESH" qualifier="genetics" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="génétique" xml:lang="fr"><term>Antigènes viraux</term><term>Protéines nucléocapside</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term><term>Épitopes</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Lymphocytes T cytotoxiques</term><term>Protéines nucléocapside</term><term>Syndrome respiratoire aigu sévère</term><term>Virus du SRAS</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term><term>Severe Acute Respiratory Syndrome</term><term>T-Lymphocytes, Cytotoxic</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Immunoglobuline G</term></keywords><keywords scheme="MESH" qualifier="virologie" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Amino Acid Sequence</term><term>Antibody Specificity</term><term>Case-Control Studies</term><term>Female</term><term>Follow-Up Studies</term><term>Gene Frequency</term><term>Genes, MHC Class I</term><term>Genes, MHC Class II</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Molecular Sequence Data</term><term>Time Factors</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Données de séquences moléculaires</term><term>Facteurs temps</term><term>Femelle</term><term>Fréquence d'allèle</term><term>Gènes MHC de classe I</term><term>Gènes MHC de classe II</term><term>Humains</term><term>Mâle</term><term>Spécificité des anticorps</term><term>Séquence d'acides aminés</term><term>Études cas-témoins</term><term>Études de suivi</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention. However, the immunological correlates associated with patients' recovery are currently unknown. In this report, we have sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our findings have direct implications for future design and development of effective therapeutic agents and vaccines against SARS-CoV infection.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17183651</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>16</Day></DateCompleted><DateRevised><Year>2018</Year><Month>11</Month><Day>13</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>1</Volume><PubDate><Year>2006</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS ONE</ISOAbbreviation></Journal><ArticleTitle>Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.</ArticleTitle><Pagination><MedlinePgn>e24</MedlinePgn></Pagination><Abstract><AbstractText>Most of the individuals infected with SARS coronavirus (SARS-CoV) spontaneously recovered without clinical intervention. However, the immunological correlates associated with patients' recovery are currently unknown. In this report, we have sequentially monitored 30 recovered patients over a two-year period to characterize temporal changes in SARS-CoV-specific antibody responses as well as cytotoxic T cell (CTL) responses. We have found persistence of robust antibody and CTL responses in all of the study subjects throughout the study period, with a moderate decline one year after the onset of symptoms. We have also identified two potential major CTL epitopes in N proteins based on ELISPOT analysis of pooled peptides. However, despite the potent immune responses and clinical recovery, peripheral lymphocyte counts in the recovered patients have not yet been restored to normal levels. In summary, our study has, for the first time, characterized the temporal and dynamic changes of humoral and CTL responses in the natural history of SARS-recovered individuals, and strongly supports the notion that high and sustainable levels of immune responses correlate strongly with the disease outcome. Our findings have direct implications for future design and development of effective therapeutic agents and vaccines against SARS-CoV infection.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Taisheng</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Infectious Disease, Peking Union Medical College Hospital and AIDS Research Center, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China; Institute of Pathogen Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China. litsh@263.net</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Jing</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yuxian</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Hongwei</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Baril</LastName><ForeName>Laurence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Zhifeng</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Yang</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Wenbing</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Weihong</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Hui</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Zuo</LastName><ForeName>Yanling</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Jian</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Zhiwei</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linqi</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U19 AI051915</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AI51915-02</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000956">Antigens, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000939">Epitopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019590">Nucleocapsid Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C099602">nucleocapsid protein, Coronavirus</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000595" MajorTopicYN="N">Amino Acid Sequence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000918" MajorTopicYN="N">Antibody Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000956" MajorTopicYN="N">Antigens, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000939" MajorTopicYN="N">Epitopes</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005805" MajorTopicYN="N">Genes, MHC Class I</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005802" MajorTopicYN="N">Genes, MHC Class II</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="N">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008969" MajorTopicYN="N">Molecular Sequence Data</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019590" MajorTopicYN="N">Nucleocapsid Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013602" MajorTopicYN="N">T-Lymphocytes, Cytotoxic</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList><GeneralNote Owner="NLM">Original DateCompleted: 20070801</GeneralNote></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>08</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>09</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>12</Month><Day>22</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17183651</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0000024</ArticleId><ArticleId IdType="pmc">PMC1762349</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>J Clin Microbiol. 2004 May;42(5):2306-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15131220</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Feb 15;189(4):648-51</Citation><ArticleIdList><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Clin Diagn Lab Immunol. 2004 Jul;11(4):665-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15242938</ArticleId></ArticleIdList></Reference><Reference><Citation>J Clin Virol. 2004 Sep;31(1):66-8</Citation><ArticleIdList><ArticleId IdType="pubmed">15288616</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Sep 15;190(6):1119-26</Citation><ArticleIdList><ArticleId IdType="pubmed">15319862</ArticleId></ArticleIdList></Reference><Reference><Citation>Emerg Infect Dis. 2005 Mar;11(3):411-6</Citation><ArticleIdList><ArticleId IdType="pubmed">15757556</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Virol. 2006 Jan;78(1):1-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16299724</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1995-2005</Citation><ArticleIdList><ArticleId IdType="pubmed">12671061</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1977-85</Citation><ArticleIdList><ArticleId IdType="pubmed">12671062</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1967-76</Citation><ArticleIdList><ArticleId IdType="pubmed">12690091</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 May 15;348(20):1953-66</Citation><ArticleIdList><ArticleId IdType="pubmed">12690092</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1394-9</Citation><ArticleIdList><ArticleId IdType="pubmed">12730500</ArticleId></ArticleIdList></Reference><Reference><Citation>Science. 2003 May 30;300(5624):1399-404</Citation><ArticleIdList><ArticleId IdType="pubmed">12730501</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2003 Jul 26;362(9380):263-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12892955</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 2004 Jul 15;190(2):379-86</Citation><ArticleIdList><ArticleId IdType="pubmed">15216476</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001F45 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001F45 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:17183651
|texte= Long-term persistence of robust antibody and cytotoxic T cell responses in recovered patients infected with SARS coronavirus.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:17183651" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |